Modelling and PBPK simulation in drug discovery. - Wikidata - awgldk - TriplyDB

Modelling and PBPK simulation in drug discovery.

Modelling and PBPK simulation in drug discovery.

http://www.wikidata.org/entity/Q37413064

about

Measurements of Deposition, Lung Surface Area and Lung Fluid for Simulation of Inhaled Compounds Novel in vitro and mathematical models for the prediction of chemical toxicity Modelling and simulation as research tools in paediatric drug development Spatio-temporal simulation of first pass drug perfusion in the liver Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification Utility of physiologically based absorption modeling in implementing Quality by Design in drug development Model-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients.In vivo imaging of systemic transport and elimination of xenobiotics and endogenous molecules in mice.Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061.Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.Translational learning from clinical studies predicts drug pharmacokinetics across patient populations.Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.The Micronutrient Genomics Project: a community-driven knowledge base for micronutrient research.A framework incorporating the impact of exposure scenarios and application conditions on risk assessment of chemicals applied to skin.BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.Maximum Recommended Dosage of Lithium for Pregnant Women Based on a PBPK Model for Lithium Absorption.Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling.Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.Quinolone Amides as Antitrypanosomal Lead Compounds with In Vivo Activity.Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin.Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levels Drug and metabolite concentrations in tissues in relationship to tissue adverse findings: a review.An industrial perspective on contemporary applications of PBPK models in drug discovery and development.Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes.Prediction of drug disposition on the basis of its chemical structure.An evaluation of the latest in vitro tools for drug metabolism studies.Physiologically Based Pharmacokinetic (Pbpk) Model of the Cyp2d6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.Assessing the bioaccumulation potential of ionizable organic compounds: Current knowledge and research priorities.Regulatory framework on bioequivalence criteria for locally acting gastrointestinal drugs: the case for oral modified release mesalamine formulations.Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.Application of PBPK modelling in drug discovery and development at Pfizer.Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery.Have physiologically-based pharmacokinetic models delivered?The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development.A fugacity-based toxicokinetic model for narcotic organic chemicals in fish.A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding.A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.

P2860

Q26738341-8C8450B0-9AB3-4922-AE37-7977F3363C33 Q26851492-B14D9B9B-BE12-4303-8A32-0B1ED00E32BC Q27010366-13760313-6F35-433F-B9C0-2E344B96EA80 Q27322901-C551834E-FFF3-4A74-8B0A-4FB600FAF18F Q28088352-3A9E802B-F224-4730-9062-8FEDB1BCE18D Q30498061-4C0C7602-4AA8-4A8E-9142-0A1813986EF7 Q30838395-9AEE6991-DC40-4FFE-9615-3E52386D7406 Q30839160-F57F11AE-0645-4E8E-8F94-EFA9B353D568 Q33456110-1EDEF1E6-948A-49A5-855A-9844931A5B13 Q33571451-0FBFE416-BA92-497C-9226-F23401635642 Q33767468-1681AF13-4AFC-4CF7-80FE-8109D6E2038F Q34181630-790FC8A0-D99C-4A56-BECA-83FDFF7E1376 Q34336738-759B0A90-ACBE-4124-9094-A98DE8C7900A Q34505158-6EEE7D21-6F43-4E6A-8D40-640F0CC3206D Q35673015-95AB719D-9389-4A0C-AC78-434B71A55E62 Q35768436-8DFD2E55-FB38-4027-8686-C22CD40FB729 Q36014275-532AD770-0AEF-4D32-9261-36D333A33B49 Q36702459-A4B760CE-097F-4DE6-B6AB-D14E5DA471D4 Q36751935-870EBE7C-3108-4CF6-8B95-5B476E0C4F47 Q37120204-499F528D-91DB-49C7-9EFD-DD8B703BE7D4 Q37559546-67376387-8C9F-4883-8C5A-1D2144B1A2B8 Q37626169-23EB0695-E776-42A1-B0C4-C3B8E4DCAC35 Q37829433-FD1ABA73-048B-4470-8237-BAF03D4D889C Q37992535-A19A3351-7796-42AF-956B-B1BAF958E006 Q38071706-B9FF9AAE-44D7-47D1-B015-E68FFE164406 Q38086778-28503D1E-A979-4C7A-B8F8-166F6773F2EB Q38160881-0675E254-10C0-48F6-B9AD-750AE50102DF Q38599220-E6C06993-85AE-41B0-AD93-9BEB15058E81 Q38758820-AC21D64D-5B53-4447-B31D-953B51CF6FC7 Q39043159-07EF534A-33F0-471D-81D9-2FAF8F5CF939 Q39401950-4274716F-455F-442B-A66D-8E4E4A4ABB26 Q39666574-629D5BC7-9B15-4371-AC0A-9F78DB1B7064 Q39692575-372FF914-A179-4DAB-BEE8-D3A4DDEFB232 Q39698362-732803FA-E50A-4581-93D3-1B7B2CAB4E77 Q39728369-6E450444-3B90-45D5-835B-DF25A0C6872A Q39769308-E3B3E6A1-52C6-44A1-B1D4-CB54FAAF7213 Q39842660-AC66FBE9-226D-477D-8D81-B3D2692B3C1C Q40359652-BDF7E31C-825A-4BEF-B6E3-B7220CEA8657 Q40592548-864AC771-BF80-43B6-B1A2-897E8F30FB0A Q40991626-E6910143-0B32-42D0-9601-C7EB983720F3

P2860

Modelling and PBPK simulation in drug discovery.

http://www.wikidata.org/entity/Q37413064

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Modelling and PBPK simulation in drug discovery.

@en

Modelling and PBPK simulation in drug discovery.

@nl

type

label

Modelling and PBPK simulation in drug discovery.

@en

Modelling and PBPK simulation in drug discovery.

@nl

prefLabel

Modelling and PBPK simulation in drug discovery.

@en

Modelling and PBPK simulation in drug discovery.

@nl

P1433

Q37413064-51C6D7EA-F819-4D0A-BC86-DB04C26F49A6

P1476

Q37413064-2845BBBA-2907-4ADD-82D4-A63E86991160

P2093

Q37413064-1117A208-3A4D-4159-AB1D-FB22716397C8

Q37413064-512ECD01-AABE-4538-BDC2-C27C85AD3E3A

Q37413064-9B1F3D98-6E5C-4891-B66C-861E4D96ACDE

P2860

Q37413064-00DEFC83-9331-4FB1-9403-9DC987589617

Q37413064-06E6C208-1F00-471A-80A1-4153230B4561

Q37413064-0D3171D6-3843-4267-91A1-1FA767B56059

Q37413064-11153A45-61CF-46A1-968D-DFC71317A5DF

Q37413064-1526245D-AF1B-4D72-BD88-C09857F39CFA

Q37413064-2035F424-2137-48FD-9FE7-809A3D846AF0

Q37413064-213A84B9-A7AE-4065-BE58-D8E3ED94475B

Q37413064-214D00C6-9B00-4F57-B4DF-1C9009B5DBBB

Q37413064-2887D434-BFCB-4A93-B98C-DE212C1E217A

Q37413064-3523FD25-4CB6-4A93-9CC8-29A5D9708F81

P2888

Q37413064-F3A23D3A-1FF5-4FC6-9794-44AADCB8A4ED

P304

Q37413064-2ED69A78-790C-4BE4-8CC4-5E20193DF9F8

P31

Q37413064-DB2436A5-8920-4F2D-A6B7-0F70684A415D

P356

Q37413064-AFE100AE-368C-4C17-95F0-151F77321E4F

P407

Q37413064-4719C622-0EA6-4859-B4CB-BFBD403F7C39

P433

Q37413064-50965B27-7DF6-4F93-8F1D-93EECCFAF8B0

P478

Q37413064-B3B4A026-638D-4297-8DBE-5882B32F78EA

P577

Q37413064-3E2C6E53-D9B9-4725-A47E-12681303FF30

P5875

Q37413064-95C28BDA-9AC9-45ED-90FE-0BB14509A566

P6179

Q37413064-3BDF9E70-0802-4B05-B89E-4FE0C7D863D9

P698

Q37413064-FF71CAA7-E22B-4ED8-8603-A32D33B6C672

P932

Q37413064-377304F7-03EA-49E6-9A45-4D9FF58F52C8

P356

S12248-009-9088-1

P1433

The AAPS Journal

P1476

Modelling and PBPK simulation in drug discovery.

@en

P2093

Hannah M Jones

http://www.w3.org/2001/XMLSchema#string

Iain B Gardner

http://www.w3.org/2001/XMLSchema#string

Kenny J Watson

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.

Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches.

A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes.

Prediction of human drug clearance from animal data: application of the rule of exponents and 'fu Corrected Intercept Method' (FCIM).

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs.

Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations.

A physiological model for the estimation of the fraction dose absorbed in humans.

Predicting the impact of physiological and biochemical processes on oral drug bioavailability.

P2888

s12248-009-9088-1

P304

155-166

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/S12248-009-9088-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24195291

http://www.w3.org/2001/XMLSchema#string

P6179

1021150367

http://www.w3.org/2001/XMLSchema#string

P698

19280352

http://www.w3.org/2001/XMLSchema#string

P932

2664888

http://www.w3.org/2001/XMLSchema#string